Literature DB >> 7540760

The relationship between pancreatic enzyme release and activation and the acute-phase protein response in patients with acute pancreatitis.

D I Heath1, A Cruickshank, A M Gudgeon, A Jehanli, A Shenkin, C W Imrie.   

Abstract

It has been suggested that the severity of an attack of acute pancreatitis is related to the presence of intraglandular trypsinogen activation and that disease severity is also reflected by the degree of the acute-phase protein response. In this study we examine the relationships among amylase release, the degree of trypsinogen and prophospholipase A2 activation [as measured by urinary trypsinogen activation peptide (TAP) and prophospholipase A2 activation peptide (PLAP) concentrations], and the serum concentrations of the acute phase-protein C-reactive protein (CRP) and the principal mediator of the acute-phase protein response, interleukin-6 (IL-6). Twenty-four patients (14 mild and 10 severe attacks) were studied. Peak serum amylase concentrations were seen within 12 h and peak urinary TAP/creatinine (Cr) and PLAP/Cr ratios between 12 and 24 h after the onset of symptoms, preceding those of IL-6 and CRP. The integrated TAP/Cr and PLAP/Cr responses were significantly greater in those with severe disease [95% confidence internal (CI) = 106-259.6 pmol/mmol/h, p < 0.0008; and 95.1% CI = 462.2-3887 pmol/mmol/h, p < 0.003, respectively]. The integrated amylase response was not significantly greater in those with severe disease (95.6% CI = -415 to 832 IU/L/h, p < 0.14). There was a strong correlation among the integrated IL-6, TAP/Cr (r = 0.63, p < 0.01), and PLAP/Cr (r = 0.64, p < 0.01) responses but a poor correlation with the integrated amylase response (r = 0.19, NS).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7540760     DOI: 10.1097/00006676-199505000-00005

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  8 in total

1.  Trypsinogen activation peptides (TAP) in peritoneal fluid as predictors of late histopathologic injury in necrotizing pancreatitis of the rat.

Authors:  J Schmidt; E Ryschich; H P Sinn; S Maksan; C Herfarth; E Klar
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

2.  Effects of high-dose intraperitoneal aprotinin treatment on complement activation and acute phase response in acute severe pancreatitis.

Authors:  R Berling; K Ohlsson
Journal:  J Gastroenterol       Date:  1996-10       Impact factor: 7.527

Review 3.  Prediction of the severity of acute pancreatitis on admission by urinary trypsinogen activation peptide: a meta-analysis.

Authors:  Wei Huang; Kiran Altaf; Tao Jin; Jun-Jie Xiong; Li Wen; Muhammad A Javed; Marianne Johnstone; Ping Xue; Christopher M Halloran; Qing Xia
Journal:  World J Gastroenterol       Date:  2013-07-28       Impact factor: 5.742

4.  Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications.

Authors:  J Mayer; B Rau; F Gansauge; H G Beger
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

5.  Effect of endothelin and endothelin receptor blockade on capillary permeability in experimental pancreatitis.

Authors:  G Eibl; H G Hotz; J Faulhaber; M Kirchengast; H J Buhr; T Foitzik
Journal:  Gut       Date:  2000-03       Impact factor: 23.059

6.  Nasogastric feeding in severe acute pancreatitis may be practical and safe.

Authors:  F C Eatock; G D Brombacher; A Steven; C W Imrie; C J McKay; R Carter
Journal:  Int J Pancreatol       Date:  2000-08

7.  Serum levels of procarboxypeptidase B and its activation peptide in patients with acute pancreatitis and non-pancreatic diseases.

Authors:  C A Müller; S Appelros; W Uhl; M W Büchler; A Borgström
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

8.  Da Cheng Qi Decoction Alleviates Cerulein-Stimulated AR42J Pancreatic Acinar Cell Injury via the JAK2/STAT3 Signaling Pathway.

Authors:  Zehua Zhou; Ying Chen; Wenmin Dong; Rui An; Kun Liang; Xinhong Wang
Journal:  Evid Based Complement Alternat Med       Date:  2021-04-09       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.